SLCTR/2016/015已完成2 期
A Phase II dose finding study in Hypnale spp with New Polyvalent Snake Antivenom (ICP-AVRI-UOP Sri Lanka polyspecific antivenom)
适应症
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients with selected clinical manifestations of envenoming by Hypnale spp. (swelling of the bitten limb with pain and/or blister formation).
排除标准
- •1. <14 years of age
- •2. Pregnancy
- •3. Already received antivenom, fresh frozen plasma (FFP), or pre-medication such as adrenaline, hydrocortisone or promethazine at the primary hospital
- •4. History of allergy to antivenom
- •5. Inability to give direct or proxy consent (unconscious and unaccompanied by a relative)
- •6. Presentation more than 8 hours after snake bite.
研究者
相似试验
进行中（未招募）
1 期
A phase 1/2 study in which, DTX-SPL8783, the trial medication will beadministered (alone or in combination with nintedanib) in order to assess the safety, tolerability, pharmacokinetics (distribution of DTX-SPL8783 in the body) and efficacy in patients with advanced malignant tumours.ocally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC).MedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 100000004864EUCTR2016-000877-19-GBStarpharma Pty Ltd.65
进行中（未招募）
1 期
A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SN38-SPL9111 (DEP®-SN38), a SN38 dendrimer conjugate, in patients with advanced solid tumours.EUCTR2019-001318-40-GBStarpharma Pty Ltd149
进行中（未招募）
1 期
A phase 1/2 study in which, CTX-SPL9111, the trial medication will be administered to evaluate the safety, tolerability, pharmacokinetics (distribution of CTX-SPL9111 in the body) and efficacy in patients with advanced solid tumoursPatients with advanced solid tumoursMedDRA version: 20.0 Level: LLT Classification code 10007050 Term: Cancer System Organ Class: 100000004864EUCTR2017-003424-76-GBStarpharma Pty Ltd33
已完成
不适用
A phase II dose-response study to assess the safety and efficacy of SJP-0035 in patients with corneal epithelial disorderCorneal epithelial disorderJPRN-UMIN000034199Senju Pharmaceutical Co.,Ltd.90
Enrolling By Invitation
1 期
K cells for the treatment of neuroblastomaHigh risk neuroblastomaNK cellNeuroblastomaTCTR20160918001TCELS15